{"id":"infanrix-ipv","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Injection site pain, redness, or swelling"},{"rate":"10-30","effect":"Fever"},{"rate":"10-30","effect":"Irritability or fussiness"},{"rate":"5-20","effect":"Drowsiness"},{"rate":"5-15","effect":"Loss of appetite"}]},"_chembl":{"chemblId":"CHEMBL6068350","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus particles. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these four pathogens. This provides immunological protection against diphtheria, tetanus, pertussis, and poliomyelitis.","oneSentence":"Infanrix IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and inactivated poliovirus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:39.839Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in infants and children"}]},"trialDetails":[{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07213089","phase":"PHASE2, PHASE3","title":"Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"BioNet-Asia Co., Ltd.","startDate":"2020-07-13","conditions":"Pertussis Whooping Cough","enrollment":290},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04300192","phase":"PHASE4","title":"Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-01-27","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":273},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT04535037","phase":"PHASE4","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-26","conditions":"Diphtheria","enrollment":500},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT03530124","phase":"PHASE4","title":"Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-07-17","conditions":"Apnea, Apnea Neonatal, Prematurity","enrollment":223},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06184542","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine","status":"RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-12-23","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":460},{"nctId":"NCT02458183","phase":"PHASE3","title":"Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-02-02","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":476},{"nctId":"NCT01568060","phase":"","title":"Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-21","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":645},{"nctId":"NCT05432141","phase":"PHASE4","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-06-13","conditions":"Poliomyelitis","enrollment":3200},{"nctId":"NCT04099303","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-28","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":400},{"nctId":"NCT01129362","phase":"","title":"Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-02-08","conditions":"Pertussis","enrollment":1195},{"nctId":"NCT03578120","phase":"","title":"Immunising Mums Against Pertussis 3","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2018-04-24","conditions":"Whooping Cough, Maternal Vaccine Exposure, Immunization; Infection","enrollment":64},{"nctId":"NCT02697474","phase":"PHASE3","title":"Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-02","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT03606096","phase":"PHASE4","title":"Gambia Pertussis Study (GaPs)","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-01-23","conditions":"Pertussis","enrollment":600},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT01358825","phase":"PHASE4","title":"Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05-30","conditions":"Tetanus, Poliomyelitis, Haemophilus Influenzae Type b","enrollment":58},{"nctId":"NCT03697798","phase":"PHASE4","title":"A Study Exploring Whooping Cough Protection in Children and Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-04-18","conditions":"Pertussis","enrollment":122},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT04636827","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-11","conditions":"Vaccination","enrollment":600},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300},{"nctId":"NCT02145624","phase":"PHASE4","title":"A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2014-10","conditions":"Responses to Infant Immunisations","enrollment":366},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT01453998","phase":"PHASE2","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-14","conditions":"Acellular Pertussis, Hepatitis B, Haemophilus Influenzae Type b","enrollment":657},{"nctId":"NCT00454987","phase":"PHASE4","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-16","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine","enrollment":288},{"nctId":"NCT00148941","phase":"PHASE3","title":"Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-06","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":4209},{"nctId":"NCT01171989","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-18","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":391},{"nctId":"NCT01577732","phase":"PHASE3","title":"Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-08","conditions":"Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus","enrollment":321},{"nctId":"NCT00489554","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":230},{"nctId":"NCT00352963","phase":"PHASE3","title":"Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-30","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":480},{"nctId":"NCT00609492","phase":"PHASE3","title":"Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":245},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":"Hepatitis B, Acellular Pertussis, Tetanus","enrollment":1437},{"nctId":"NCT01353703","phase":"PHASE3","title":"Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-16","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":224},{"nctId":"NCT01153841","phase":"PHASE3","title":"Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":300},{"nctId":"NCT01309646","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-04","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":454},{"nctId":"NCT00753649","phase":"PHASE4","title":"Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-23","conditions":"Hepatitis B, Tetanus, Poliomyelitis","enrollment":224},{"nctId":"NCT02858440","phase":"PHASE3","title":"A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-13","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":235},{"nctId":"NCT01340898","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-27","conditions":"Meningococcal Infection","enrollment":753},{"nctId":"NCT00466947","phase":"PHASE3","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-28","conditions":"Infections, Streptococcal","enrollment":23802},{"nctId":"NCT00652951","phase":"PHASE3","title":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-01","conditions":"Infections, Streptococcal","enrollment":780},{"nctId":"NCT03982732","phase":"","title":"Maternal Antibody in Milk After Vaccination","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2018-08-07","conditions":"Pertussis, Vaccination, Pregnancy","enrollment":50},{"nctId":"NCT00370396","phase":"PHASE3","title":"Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-25","conditions":"Infections, Streptococcal","enrollment":1200},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":"Infections, Streptococcal","enrollment":576},{"nctId":"NCT01235949","phase":"PHASE4","title":"Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-12","conditions":"Infections, Streptococcal","enrollment":850},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT02526394","phase":"PHASE4","title":"Pertussis and Meningitis C Concomitant Vaccination in Adolescents","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-09","conditions":"Pertussis, Meningitis, Preventive Immunization; Meningitis","enrollment":400},{"nctId":"NCT01094171","phase":"PHASE4","title":"Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-03","conditions":"Poliomyelitis","enrollment":400},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT01323647","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-25","conditions":"Poliomyelitis","enrollment":957},{"nctId":"NCT00496015","phase":"PHASE3","title":"Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":"Infections, Streptococcal","enrollment":750},{"nctId":"NCT00345358","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-18","conditions":"Infections, Streptococcal","enrollment":600},{"nctId":"NCT00513409","phase":"PHASE2","title":"Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-22","conditions":"Infections, Streptococcal","enrollment":163},{"nctId":"NCT00390910","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-01","conditions":"Infections, Streptococcal","enrollment":286},{"nctId":"NCT00290342","phase":"PHASE3","title":"Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-01","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":458},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT01119625","phase":"PHASE3","title":"Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-12","conditions":"Infections, Streptococcal","enrollment":238},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00586612","phase":"PHASE3","title":"Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":313},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT01248884","phase":"PHASE2","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-09","conditions":"Tetanus, Poliomyelitis, Hepatitis B","enrollment":721},{"nctId":"NCT01138098","phase":"PHASE4","title":"Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-07","conditions":"Hepatitis B","enrollment":185},{"nctId":"NCT01245049","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Acellular Pertussis, Poliomyelitis, Tetanus","enrollment":387},{"nctId":"NCT00808444","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-05","conditions":"Infections, Streptococcal","enrollment":466},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":"Infections, Papillomavirus","enrollment":751},{"nctId":"NCT00307034","phase":"PHASE3","title":"Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-01","conditions":"Infections, Streptococcal","enrollment":351},{"nctId":"NCT00533507","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-18","conditions":"Infections, Rotavirus","enrollment":230},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT01323959","phase":"PHASE4","title":"Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Acellular Pertussis, Poliomyelitis, Diphtheria","enrollment":212},{"nctId":"NCT00635128","phase":"PHASE4","title":"Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-01","conditions":"Poliomyelitis, Diphtheria, Tetanus","enrollment":415},{"nctId":"NCT00871000","phase":"PHASE3","title":"Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":303},{"nctId":"NCT00611559","phase":"PHASE4","title":"Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-14","conditions":"Poliomyelitis, Acellular Pertussis, Tetanus","enrollment":283},{"nctId":"NCT00627458","phase":"PHASE2","title":"Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-01","conditions":"Acellular Pertussis, Diphtheria, Poliomyelitis","enrollment":403},{"nctId":"NCT01086423","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-01","conditions":"Tetanus, Poliomyelitis, Acellular Pertussis","enrollment":985},{"nctId":"NCT00325143","phase":"PHASE3","title":"Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-01","conditions":"Haemophilus Influenzae Type b, Diphtheria, Tetanus","enrollment":702},{"nctId":"NCT00964028","phase":"PHASE3","title":"Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-12-01","conditions":"Haemophilus Influenzae Type b, Acellular Pertussis, Diphtheria","enrollment":50},{"nctId":"NCT01449812","phase":"PHASE3","title":"Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":831},{"nctId":"NCT02610348","phase":"NA","title":"Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-11","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582},{"nctId":"NCT03128489","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-12-01","conditions":"Diphtheria, Acellular Pertussis, Haemophilus Influenzae Type b","enrollment":""},{"nctId":"NCT02589678","phase":"PHASE1, PHASE2","title":"Zambia SiVET MMR Tdap-IPV","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-08","conditions":"High Risk for HIV","enrollment":160},{"nctId":"NCT01457495","phase":"PHASE2","title":"Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-09","conditions":"Hepatitis B, Diphtheria, Haemophilus Influenzae Type b (Hib)","enrollment":312},{"nctId":"NCT01457508","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-01","conditions":"Hepatitis B, Diphtheria, Haemophilus Influenzae Type b (Hib)","enrollment":440},{"nctId":"NCT00289796","phase":"PHASE2","title":"Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-07","conditions":"Hepatitis B","enrollment":121},{"nctId":"NCT00376779","phase":"PHASE2","title":"Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":450},{"nctId":"NCT00322335","phase":"PHASE3","title":"Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":230},{"nctId":"NCT02771782","phase":"PHASE4","title":"Influence of BCG on TDaP-IPV Vaccination","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2015-01","conditions":"Whooping Cough","enrollment":75},{"nctId":"NCT00338351","phase":"PHASE2","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Hepatitis A","enrollment":240},{"nctId":"NCT00258700","phase":"PHASE3","title":"Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":478},{"nctId":"NCT00366366","phase":"PHASE3","title":"To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-09","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT00729001","phase":"PHASE2","title":"Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-11","conditions":"Infections, Rotavirus","enrollment":529},{"nctId":"NCT01294605","phase":"PHASE4","title":"Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-04","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":460},{"nctId":"NCT00263692","phase":"PHASE2","title":"Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Diphtheria, Acellular Pertussis, Tetanus","enrollment":401},{"nctId":"NCT00879827","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-09","conditions":"Diphtheria, Poliomyelitis, Hepatitis B","enrollment":60},{"nctId":"NCT01277705","phase":"PHASE3","title":"Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-01","conditions":"Tetanus, Diphtheria, Acellular Pertussis","enrollment":806},{"nctId":"NCT01457560","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-02","conditions":"Hepatitis B, Acellular Pertussis, Haemophilus Influenzae Type b","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"PYREXIA"},{"count":5,"reaction":"VOMITING"},{"count":4,"reaction":"VACCINATION SITE REACTION"},{"count":3,"reaction":"FEBRILE CONVULSION"},{"count":2,"reaction":"ACUTE DISSEMINATED ENCEPHALOMYELITIS"},{"count":2,"reaction":"BODY TEMPERATURE INCREASED"},{"count":2,"reaction":"HYPOTONIC-HYPORESPONSIVE EPISODE"},{"count":2,"reaction":"INJECTION SITE ERYTHEMA"},{"count":2,"reaction":"JAUNDICE"},{"count":2,"reaction":"LYMPHADENOPATHY"}],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DTPa-IPV (GSK Biologicals)"],"phase":"marketed","status":"active","brandName":"Infanrix IPV","genericName":"Infanrix IPV","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Infanrix IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and inactivated poliovirus. Used for Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}